Investing

Solid Biosciences : SLDB

SLDB

Stock Data

$9.30

$0.20 (2.20%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Solid Biosciences Inc. focuses on creating innovative therapies for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. With a leading product candidate, SGT-003, aimed at Duchenne muscular dystrophy, the company is at the forefront of gene therapy research. It also explores treatments for cardiac conditions like BAG3-mediated dilated cardiomyopathy. Based in Massachusetts, Solid Biosciences is pioneering in dual gene expression technology and has partnerships to advance gene therapy development.

All Solid Biosciences Articles

2 Articles

Trey Thoelcke | Feb 18, 2024 at 11:20 AM EST

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted…

Trey Thoelcke | Jan 20, 2024 at 10:49 AM EST

More Big Warren Buffett Purchases Highlight Recent Insider Buying

Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.